management of hospitalized intravenous drug users: role of the internist.

NLM AIDSLINE Management of hospitalized intravenous drug users: role of the internist. O'Connor PG; Samet JH; Stein MD; Department of Medicine, Yale University
September 30, 1994

Am J Med. 1994 Jun;96(6):551-8. Unique Identifier : AIDSLINE Intravenous drug users present significant clinical challenges to internists. In this paper, we review common clinical dilemmas faced by internists when managing intravenous drug users in the inpatient hospital setting. Articles were identified through a MEDLINE search and bibliographies of published articles. Studies and reviews were selected for information relevant to the management of hospitalized intravenous drug users. Seventy-three papers were selected for this review. We summarize data and information from the relevant literature concerning common presenting medical problems (fever, musculoskeletal pain, and dyspnea), the importance of knowing patients' HIV status, common behavioral issues, special concerns of women, and the diagnosis and management of drug withdrawal in intravenous drug users. We also offer recommendations for hospital discharge planning. With appropriate knowledge of the epidemiology and management of important medical and substance use problems among intravenous drug users, internists may more effectively care for them in the hospital setting. Dyspnea/THERAPY Female Fever/THERAPY Hospitalization Human Internal Medicine Musculoskeletal Diseases/THERAPY Pain/THERAPY Patient Discharge Physician's Role Substance Abuse, Intravenous/COMPLICATIONS Substance Withdrawal Syndrome/ETIOLOGY/THERAPY JOURNAL ARTICLE REVIEW REVIEW, TUTORIAL

Most Read: Latest Added Related Topics White House LGBT Conference on HIV/AIDS UNITED STATES: White House in Atlanta: LGBT AIDS Conference No more single-theme conferences: global HIV prevention conference planned FHI 360 Senior Scientist Lut Van Damme Receives International Microbicide Conference Lifetime Achievement Award Equatorial Guinea Ministry of Health and Social Welfare and UNICEF Refute Erroneous AIDS Prevalence Figures Photographs from A Day with HIV Now Online Bulgaria urges Libya to investigate AIDS nurses case Engineers enter fight against AIDS in Africa Gilead’s Complera® Non-Inferior to Atripla® Among Treatment-Naive HIV Patients UN chief Ban calls world leaders to end Aids by 2020 SWITZERLAND: Swiss TB Rate Below European Average SOUTH CAROLINA: DHEC Orders North Charleston Clinic to Halt Invasive Procedures CANADA: New Facility Unveiled for Homeless With Hepatitis C FLORIDA: Gospel of Health: Block Party Promotes HIV and AIDS Awareness CALIFORNIA: 2Cents Theatre Group Announces Plans to Benefit HIV/AIDS Organizations with RENT UNITED STATES: HCV Prevalence Higher Among Asian-Americans WALES: HIV Patients Are at Risk of Being Identified Because of New Prescribing System, Warns AM MICHIGAN: Michigan Department of Community Health Encourages Testing for America's Silent Epidemic: Viral Hepatitis Fight Breast Cancer and More at Walk The World, A First of Its Kind Walkathon at The Walt Disney World Resort in Florida When it comes to deadly viruses, what's in a name? Study Finds Vitamin C Can Kill Drug-Resistant TB Immune system cancer drugs tipped to be a $35 billion market NEW JERSEY: Drug Company Donates Thousands to HIV/AIDS Orgs NORTH KOREA: North Korea Sees Surge of Drug-Resistant Tuberculosis Experimental Gilead drug effective in early-stage leukemia trial Public Meeting on HIV Patient-Focused Drug Development and HIV Cure Research: June 14, 2013 India's Largest Generic Drugmaker Ranbaxy Pays $500 Million to Settle Systemic Generic Drug Manufacturing Fraud AHF Shareholder Advocates Challenge Gilead on Drug Pricing at AGM 2012 US medicine sales show shifts by drug type Drug industry CEOs plotting more carve-outs
Information in this article was accurate in September 30, 1994. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.